Answers are grounded in this paper and cite their sources.
Falsification study reveals that gene expression dispersion does not reliably predict survival in glioblastoma, suggesting structural validation is crucial.
This study investigates whether patient-level gene expression dispersion (coefficient of variation, CV) represents a biologically meaningful survival signal or an emergent statistical property of high-dimensional data. Using TCGA glioblastoma (GBM), the CV metric significantly stratifies survival. However, systematic falsification—including random gene controls, permutation-based structure destruction, cross-cancer testing, network analysis, spectral decomposition, predictive validation, and high-dimensional geometry—demonstrates that the signal is context-dependent, non-generalizable, weakly predictive, and not supported by pathway or network structure. These findings show that survival signals can arise from aggregation effects in high-dimensional systems and emphasize the need for structural validation in omics research.
No takes yet. Share an insight, caveat, or question.
Thomas S. Mitchell (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: